Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Trial Profile

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Retinal pigment epithelial cell replacement therapy-Cell Cure Neurosciences (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Cell Cure Neurosciences
  • Most Recent Events

    • 25 Jul 2017 According to a BioTime media release, for cohort 3 optimization of the implant for cell concentration and volume is ongoing. The company expects to start enrolling patients in cohort 3 in the coming weeks and complete during the fourth quarter of 2017.
    • 25 Jul 2017 According to a BioTime media release, the Data Safety Monitoring Board (DSMB) has authorized the Company to move forward with enrollment for cohort 3. Dr. David S. Boyer and Dr. H. Richard McDonald will lead this cohort.
    • 19 Jul 2017 According to a BioTime media release, data from this trial will be presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top